Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Clin Exp Rheumatol ; 35(3): 462-470, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28240588

RESUMEN

OBJECTIVES: The current strategy for antinuclear antibody (ANA) analysis involves screening for presence with a subsequent detailed analysis of their specificity. The aim of this study is to compare the clinical and financial efficacy of this strategy between different commercial tests in a large cohort of unselected patients. METHODS: In all consecutive 1030 patients associations were defined between results from different ANA test systems and the pre-test probability for connective tissue disease (CTDs). Test systems were used for screening (ANA-IIF vs. CTD screen) and definition of their fine specificity (profile 3 line blot vs. CTD single analytes). RESULTS: Positive ANA-IIF and/or CTD screen results were found in 304 sera. Further analysis for ANA-specificity by profile 3 line blot and CTD single analytes showed 86 discrepant results of which more than a third are clinically relevant, with the CTD single analyte assay performing better than the line blot in supporting or confirming the presence of a CTD. Autoantigens present in one test but absent in the other were of minor practical use. The ANA screening and identification strategies currently employed are not cost-effective as 83% of tests were performed in order to find specific autoantibodies in patients without the fitting clinical signs or symptoms. This causes many unexpected positive results and subsequent confusion with regard to interpretation. CONCLUSIONS: We advocate that some autoantigens should be excluded from the line blot and CTD assays and propose the use of a cost-effective and selective ANA specificity testing purely based on clinical guidance.


Asunto(s)
Anticuerpos Antinucleares/sangre , Enfermedades Autoinmunes/diagnóstico , Enfermedades del Tejido Conjuntivo/diagnóstico , Juego de Reactivos para Diagnóstico , Pruebas Serológicas , Especificidad de Anticuerpos , Enfermedades Autoinmunes/sangre , Enfermedades Autoinmunes/inmunología , Biomarcadores/sangre , Enfermedades del Tejido Conjuntivo/sangre , Enfermedades del Tejido Conjuntivo/inmunología , Análisis Costo-Beneficio , Costos de la Atención en Salud , Humanos , Valor Predictivo de las Pruebas , Juego de Reactivos para Diagnóstico/economía , Reproducibilidad de los Resultados , Pruebas Serológicas/economía
2.
Chronobiol Int ; 39(10): 1329-1339, 2022 10.
Artículo en Inglés | MEDLINE | ID: mdl-36004426

RESUMEN

The postprandial glycemic response is an important metabolic health factor, which, from laboratory studies, is known to change from low to high over the course of the day, and from which negative health outcomes have been linked to nightly eating. We applied interstitial continuous glucose monitoring to examine the glycemic response to a standardized carbohydrate-rich snack (198 kcal) across the day in a real-life setting. Twenty-four healthy participants (12 men, 12 women, 27-61 y old) consumed the snack nine times during 6 d in a crossover design, altering the time of consumption between morning, afternoon and evening. The snack was consumed in the participant's own environment with a preceding fast of at least 2.5 h between their customary main meals and practices. Linear mixed models were used with fixed effect of timing, and participant as random effect, to assess incremental area under the curve, peak value and time-to-peak of the glycemic response. Overall, the highest glycemic excursions were observed in the morning, while a more dampened but prolonged response was observed in the evening. These findings do not concur with previously published laboratory studies. This implies that results obtained under controlled experimental conditions in laboratories cannot be generalized directly to predict chrononutritional effects on the glycemic response in healthy individuals and their daily routines.


Asunto(s)
Glucemia , Bocadillos , Adulto , Glucemia/metabolismo , Automonitorización de la Glucosa Sanguínea , Ritmo Circadiano/fisiología , Estudios Cruzados , Femenino , Índice Glucémico/fisiología , Humanos , Insulina , Masculino , Periodo Posprandial/fisiología , Bocadillos/fisiología
3.
Biotechnol Bioeng ; 104(1): 143-51, 2009 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-19475676

RESUMEN

Toxic-shock syndrome is primarily caused by the Toxic-shock syndrome toxin 1 (TSST-1), which is secreted by the Gram-positive bacterium Staphylococcus aureus. The toxin belongs to a family of superantigens (SAgs) which exhibit several shared biological properties, including the induction of massive cytokine release and V(beta)-specific T-cell proliferation. In this study we explored the possibility to use monoclonal Variable domains of Llama Heavy-chain antibodies (VHH) in the immuno capturing of TSST-1 from plasma. Data is presented that the selected VHHs are highly specific for TSST-1 and can be efficiently produced in large amounts in yeast. In view of affinity chromatography, the VHHs are easily coupled to beads, and are able to deplete TSST-1 from plasma at very low, for example, pathologically relevant, concentrations. When spiked with 4 ng/mL TSST-1 more than 96% of TSST-1 was depleted from pig plasma. These data pave the way to further explore application of high-affinity columns in the specific immuno depletion of SAgs in experimental sepsis models and in sepsis in humans.


Asunto(s)
Antígenos Bacterianos/aislamiento & purificación , Toxinas Bacterianas/aislamiento & purificación , Cromatografía de Afinidad/métodos , Enterotoxinas/aislamiento & purificación , Plasma/química , Staphylococcus aureus/patogenicidad , Superantígenos/aislamiento & purificación , Animales , Anticuerpos Monoclonales/inmunología , Antígenos Bacterianos/inmunología , Toxinas Bacterianas/inmunología , Camélidos del Nuevo Mundo , Enterotoxinas/inmunología , Enterotoxinas/metabolismo , Humanos , Unión Proteica , Sensibilidad y Especificidad , Superantígenos/inmunología
4.
Shock ; 37(3): 247-52, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22129566

RESUMEN

Severe sepsis is characterized by rapid development of multiple organ failure associated with high mortality. Bacterial toxin release triggers a sequence of events that activates intracellular pathways to produce inflammatory mediators and nitric oxide. There have been numerous attempts to interrupt this devastating cascade by removing toxins, removing or inhibiting mediators, and by blocking receptors of mediators. This review considers toxin properties with a strong focus on toxic shock syndrome toxin 1 and the potential of various removal technologies in relation to these properties. The distribution of toxins in vivo forms a key issue but is nevertheless poorly defined. For toxic shock syndrome toxin 1, either a high clearance or a high degree of compartmentalization to a space not accessible by pheresis or immunoabsorption technologies seems likely. Attempts to remove toxins to treat sepsis may appear futile if we cannot access this space or when the level of induced clearance is too low compared with natural clearance. The impact of these considerations is highly dependent on the exact toxin biology in vivo. Extrapolated to other toxins, we indicate a set of general requirements to be met to facilitate successful toxin removal by a pheresis technique.


Asunto(s)
Toxinas Bacterianas/aislamiento & purificación , Enterotoxinas/aislamiento & purificación , Sepsis/terapia , Superantígenos/aislamiento & purificación , Toxinas Bacterianas/inmunología , Toxinas Bacterianas/metabolismo , Enterotoxinas/inmunología , Enterotoxinas/metabolismo , Humanos , Plasmaféresis/métodos , Superantígenos/inmunología , Superantígenos/metabolismo
5.
Shock ; 34(2): 125-32, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20016410

RESUMEN

Staphylococcus aureus produces the superantigen toxic shock syndrome toxin 1 (TSST-1). When the bacterium invades the human circulation, this toxin can induce life-threatening gram-positive sepsis. Current sepsis treatment does not remove bacterial toxins. Variable domains of llama heavy-chain antibodies (VHH) against toxic shock syndrome toxin 1 ([alpha]-TSST-1 VHH) were previously found to be effective in vitro. We hypothesized that removing TSST-1 with [alpha]-TSST-1 VHH hemofiltration filters would ameliorate experimental sepsis in pigs. After assessing in vitro whether timely removing TSST-1 interrupted TSST-1-induced mononuclear cell TNF-[alpha] production, VHH-coated filters were applied in a porcine sepsis model. Clinical course, survival, plasma interferon [gamma], and TSST-1 levels were similar with and without VHH-coated filters as were TSST-1 concentrations before and after the VHH filter. Plasma TSST-1 levels were much lower than anticipated from the distribution of the amount of infused TSST-1, suggesting compartmentalization to space or adhesion to surface not accessible to hemofiltration or pheresis techniques. Removing TSST-1 from plasma was feasible in vitro. However, the [alpha]-TSST-1 VHH adsorption filter-based technique was ineffective in vivo, indicating that improvement of VHH-based hemofiltration is required. Sequestration likely prevented the adequate removal of TSST-1. The latter warrants further investigation of TSST-1 distribution and clearance in vivo.


Asunto(s)
Cadenas Pesadas de Inmunoglobulina/uso terapéutico , Fragmentos de Péptidos/uso terapéutico , Choque Séptico/prevención & control , Animales , Toxinas Bacterianas , Camélidos del Nuevo Mundo/inmunología , Células Cultivadas , Enterotoxinas , Femenino , Hemofiltración/métodos , Humanos , Leucocitos Mononucleares/metabolismo , Choque Séptico/inmunología , Superantígenos , Sus scrofa
6.
ASAIO J ; 55(6): 575-80, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19812475

RESUMEN

Intradialytic hypotension is often caused by a discrepancy between ultrafiltration and plasma refilling. Increasing the plasma refill rate could therefore reduce intradialytic hypotension. We used a recently developed method to measure the effect of cool dialysate and sodium (Na) profiling on refill during hemodialysis (HD). Using a Gambro AK200 with blood volume (BV) sensor plus computer-guided external pump, a high ultrafiltration rate quickly induced a preset BV reduction. A software feedback mechanism subsequently adjusted the ultrafiltration rate continuously to maintain BV between very narrow preset boundaries. The continuously changing, software-generated ultrafiltration rate then quantitatively equalled refill. Absolute plasma refill rate was measured in six stable patients without intradialytic hypotension, undergoing HD without intervention, with cool dialysate (1 degrees C below core temperature), and with Na profiling (gradually declining from 150 to 140 mmol/l). Baseline refill rate was 20.1 + or - 4.0 ml/min (mean + or - SD). Although cool dialysate did not affect refill (22.2 + or - 4.1 ml/min, p = 0.27 vs. baseline), Na profiling induced a significant improvement (26.8 + or - 3.7 ml/min, p = 0.006 vs. baseline). Using our method to measure absolute plasma refill rate during HD, we demonstrated that Na profiling indeed improves the plasma refill rate. A potential effect of cool dialysate could not be established.


Asunto(s)
Soluciones para Diálisis/química , Hipotensión/prevención & control , Diálisis Renal/efectos adversos , Diálisis Renal/métodos , Sodio/análisis , Humanos , Hipotensión/etiología
7.
ASAIO J ; 54(1): 95-9, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18204322

RESUMEN

Methods to continuously measure absolute refill during dialysis are not available. It would be useful to have such a method because it would allow investigating the mechanism of refill the effect of interventions. We designed a feedback algorithm that adjusts ultrafiltration rate (QUF) according to hemoglobin (Hb) concentration changes in such a way that relative blood volume (BV) remains constant within a narrow target range. In this situation, the generated QUF quantitatively reflects refill. Refill patterns were studied in five hypotension prone patients. In addition, on separate occasions, we studied the effect of antiembolism stockings (AES) and infusion of hydroxy-ethylated starch (HAES) on refill in these patients. Refill during the first hour fell significantly from 21 +/- 3 ml/min to 9 +/- 2 ml/min (p < 0.05). In the second hour, refill decreased further and became zero in four out of five patients. Neither AES nor HAES measurably affected refill. The marked and rapid fall in refill in the early stages of dialysis suggests untimely depletion of the interstitial compartment and underestimation of dry weight. We propose that continuous, online measurement of refill patterns may be of value for accurate estimation of dry weight in dialysis patients.


Asunto(s)
Hemodiafiltración/instrumentación , Diálisis Renal/instrumentación , Diálisis Renal/métodos , Ultrafiltración/instrumentación , Anciano , Anciano de 80 o más Años , Volumen Sanguíneo , Hemodiafiltración/métodos , Soluciones para Hemodiálisis/farmacología , Hemoglobinas/química , Humanos , Derivados de Hidroxietil Almidón/química , Hipotensión/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Sistemas en Línea , Reproducibilidad de los Resultados , Ultrafiltración/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA